Myelodysplastic Syndromes

New Revimid data shows potential as MDS treatment

Published in Blood Weekly, June 12th, 2003

Data presented at the Seventh International Symposium on Myelodysplastic Syndromes in Paris demonstrated Revimid (CC-5013) as a potential new agent for treating myelodysplastic syndromes (MDS).

MDSs are malignant disorders of blood cell production and affect approximately 250,000-300,000 people worldwide, and which eventually lead to acute leukemia. The study shows that Revimid reduced or eliminated the need for red blood cell transfusions in anemic patients who had been using transfusions.

"This oral agent is the first therapy, in clinical studies, to demonstrate an impact on the red blood cell production of MDS patients with anemia, allowing them...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry